Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Enliven Therapeutics (NASDAQ:ELVN) had its price objective hoisted by analysts at Robert W. Baird from $32.00 to $40.00 in a report released on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s price objective would suggest a potential upside of 63.87% from the company’s current price.

Separately, HC Wainwright reissued a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday, October 1st.

Enliven Therapeutics Trading Down 2.0 %

Shares of Enliven Therapeutics stock opened at $24.41 on Friday. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -12.85 and a beta of 1.08. The business’s 50 day simple moving average is $26.28 and its 200-day simple moving average is $23.94. Enliven Therapeutics has a twelve month low of $9.80 and a twelve month high of $30.03.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 847 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $30.00, for a total value of $25,410.00. Following the completion of the sale, the insider now directly owns 1,015,188 shares in the company, valued at $30,455,640. The trade was a 0.08 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock in a transaction on Monday, August 26th. The shares were sold at an average price of $22.89, for a total transaction of $274,680.00. Following the completion of the sale, the chief executive officer now directly owns 1,049,255 shares of the company’s stock, valued at approximately $24,017,446.95. The trade was a 1.13 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 152,195 shares of company stock valued at $4,091,454 in the last 90 days. 29.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Quest Partners LLC boosted its position in Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after purchasing an additional 742 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Enliven Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock worth $232,000 after buying an additional 3,559 shares during the period. EntryPoint Capital LLC acquired a new position in Enliven Therapeutics in the 1st quarter valued at $167,000. SG Americas Securities LLC bought a new position in Enliven Therapeutics in the 3rd quarter worth $256,000. Finally, Verition Fund Management LLC acquired a new position in Enliven Therapeutics during the 3rd quarter worth $271,000. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.